ESC Premium Access

Determinants of pulmonary vascular resistance reduction with upfront oral therapy in idiopathic pulmonary arterial hypertension: relevance in risk assessment

Congress Presentation

About the speaker

Associate Professor Roberto Badagliacca

Sapienza University of Rome, Rome (Italy)
1 presentation
0 follower

2 more presentations in this session

Outcomes associated with modern treatment paradigms in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH): a meta-analysis of randomized controlled trials (RCTs)

Speaker: Doctor V. McLaughlin (Ann Arbor, US)


Lowering of mean pulmonary arterial pressure is a prognostic marker in pulmonary hypertension patients treated with subcutaneous treprostinil

Speaker: Doctor R. Sadushi-Kolici (Vienna, AT)


Access the full session

Advances in the Management of Pulmonary Arterial Hypertension

Speakers: Associate Professor R. Badagliacca, Doctor V. McLaughlin, Doctor R. Sadushi-Kolici

About the event


ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Related content

Open Access

Long-term outcomes in PAH: Optimised approach to achieve the best outcomes.

27 August 2021

ESC Premium Access

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

27 August 2021

ESC Premium Access

Impact of COVID-19 pandemics upon pulmonary hypertension patients: insights from BNP-PL national database

27 August 2021

ESC 365 is supported by

logo Novo Nordisk